SMD Rise Public Company (SMD100) Fair Value & Analysis
Healthcare · TH · Market cap 235M THB
Fair value as of: Jul 15, 2026
From 15 valuation models · updated 26 days ago
Fair value updated Jul 15, 2026, revised from 1.41 THB to 1.02 THB (−27.7%) since Jun 24, 2026. Share price +0.9% over the past month.
Below-average quality, and screening another 11% overvalued on our models.
What matters now
- Our model range runs from 0.7700 THB (bear) to 1.25 THB (bull), base 1.02 THB. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 44/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range 1.07 THB – 10.72 THB · fair‑value band 0.7700 THB – 1.25 THB · the 1.15 THB price screens above the 1.02 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
SMD Rise Public Company (SMD100) currently trades at 1.15 THB, while our model-based Fair Value estimate is 1.02 THB, implying the stock looks roughly 11.3% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, SMD Rise Public Company generated revenue of 931M THB at a net margin of 0.7%. Revenue grew 13.5% year over year. It earns a return on equity of 0.9%. Net debt stands at 193M THB. Fundamentals as of Jul 15, 2026
Our scenario range runs from 0.7700 THB (bear case) to 1.25 THB (bull case); at 1.15 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -11%, SMD100 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Asset-Based (2.31 THB) versus Earnings-Based (0.5500 THB). Highest evidence: Residual Income (76).
Notify me when SMD100 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SMD Rise Public Company Limited engages in the import and distribution of medical devices, equipment, and supplies in Thailand. The company is involved in providing sleep testing services; and rental, hire purchase, and leasing of the medical equipment, as well as offers wellness equipment services.
Full company description
SMD Rise Public Company Limited engages in the import and distribution of medical devices, equipment, and supplies in Thailand. The company is involved in providing sleep testing services; and rental, hire purchase, and leasing of the medical equipment, as well as offers wellness equipment services. It also imports and distributes products related to radiology and other similar medical products. In addition, the company designs and develops software and information technology systems. Further, it imports and distributes automated medication dispensing machines, pharmaceutical products, medical robots, vascular technologies and equipment, and other related devices. The company was formerly known as SaintMed Public Company Limited and changed its name to SMD Rise Public Company Limited in January 2025. The company was founded in 1998 and is based in Nonthaburi, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SMD Rise Public Company reported revenue of 910M THB in FY2025 versus 1.6B THB in FY2021, a compound −13.4%/yr. Reported net income was 10.6M THB in FY2025, compounding −57.3%/yr from FY2021.
SMD100 screens 11% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare SMD Rise Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SMD Rise Public Company (SMD100) overvalued or undervalued?
What is the fair value of SMD100?
What is the quality score of SMD100?
What is the revenue of SMD Rise Public Company (SMD100)?
What is the net profit margin of SMD100?
Does SMD Rise Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SMD Rise Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.